Published April 1, 2026 | Version v1
Journal article Open

AN OVERVIEW: PHARMACOVIGILANCE IN A TERTIARY CARE FACILITY IN NEW DELHI

Authors/Creators

  • 1. Coordinator, Pharmacovigilance, Indian Spinal Injury Centre, New Delhi.
  • 2. Deputy Coordinator, Pharmacovigilance, Indian Spinal Injury Centre, New Delhi.

Description

Introduction: Adverse drug reactions (ADRs) are harmful, unintended drug responses occurring at standard therapeutic doses. They pose a major global health and economic burden, especially among older adults. Prevention is feasible through systematic interventions—particularly pharmacist-led—and by strengthening pharmacovigilance systems at national and international levels. Addressing ADRs effectively improves patient safety, reduces healthcare costs, and optimizes therapeutic outcomes. Material and Methods: ADRs that took place in admitted patients were taken into consideration for analysis. Information about ADR was collected in the ADR reporting form. Result: From January to July 2025, 32 ADRs were reported. The age of patients who underwent ADR ranged between 16 and 83 years. All the ADRs were divided into three categories based upon severity, and the highest number of ADR (85%) belong to the mild category, whereas 9% and 6% of ADR belong to the moderate and severe categories. Conclusion: ADR reporting is a critical component of pharmacovigilance, ensuring safe and effective use of medicines in real-world practice. Timely reporting by healthcare professionals, patients, and institutions helps identify risks that may not have been detected during clinical trials.

Files

2 An Overview Pharmacovigilance in a Tertiary Care Facility in New Delhi.pdf

Files (904.1 kB)

Additional details

References

  • 1. Alomar, M., Palaian, S., & Al-tabakha, M. M., Pharmacovigilance in perspective: Drug withdrawals, data mining and policy implications. In F1000 Research, 2019; 8. F1000 Research Ltd.
  • 2. Beijer, H. J. M., & de Blaey, C. J., Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science, 2002; 24(2): 46–54.
  • 3. Edwards, I. R., & Aronson, J. K., Adverse drug reactions: definitions, diagnosis, and management. The Lancet, 2000; 356(9237): 1255–1259.
  • 4. JOSE, J., & RAO, P., Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacological Research, 2006; 54(3): 226–233.
  • 5. Lhamo, Y., Purohit, K., Singh, S., Chopra, D., & Bharti, M., Pattern, severity, and preventability of adverse drug reactions from a Northern Indian tertiary care facility: A retrospective analysis. International Journal of Risk & Safety in Medicine, 2025; 36(1): 5–13.
  • 6. Patel, T., Thakkar, S., & Sharma, D., Cutaneous adverse drug reactions in Indian population: A systematic review. Indian Dermatology Online Journal, 2014; 5(6): 76.
  • 7. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, K., & Breckenridge, A. M. (n.d.). Papers Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.
  • 8. Rademaker, M., Do Women Have More Adverse Drug Reactions? American Journal of Clinical Dermatology, 2001; 2(6): 349–351.
  • 9. Routledge, P. A., O'Mahony, M. S., & Woodhouse, K. W., Adverse drug reactions in elderly patients. In British Journal of Clinical Pharmacology, 2004; 57(2): 121–126. Safety of Medicines. (2002).
  • 10. Zopf, Y., Rabe, C., Neubert, A., Gaßmann, K. G., Rascher, W., Hahn, E. G., Brune, K., & Dormann, H., Women encounter ADRs more often than do men. European Journal of Clinical Pharmacology, 2008; 64(10): 999–1004.